 CAMBRIDGE, Mass. and NEW YORK, Aug. 05, 2020 GLOBE NEWSWIRE -- Black Diamond Therapeutics, Inc. Nasdaq: BDTX, a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Companys progress at the following upcoming investor conferences: The 2020 Wedbush PacGrow Healthcare Conference. The presentation will take place on Wednesday, August 12, 2020, at 10:20 AM ET. The 40th Annual Canaccord Genuity Growth Conference. The presentation will take place on Thursday, August 13, 2020, at 3:30 PM ET.Live webcasts of each presentation can be accessed by visiting the investor relations section of the Companys website, A replay of each presentation will also be available and archived on the site for three weeks.About Black Diamond Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Companys proprietary technology platform, Mutation-Allostery-Pharmacology, or MAP, platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families, and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations. Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth Buck, Ph.D., and, beginning in 2017, together with Versant Ventures, began building the MAP platform and chemistry discovery engine. For more information, please visit Investors: Natalie Wildenradt Media: Kathy Vincent 310 403-8951 